Relmada Therapeutics, Inc. Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
20Relmada rapeutics's Business Model
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
About Relmada rapeutics
Website: https://www.relmada.com
CEO (Chief Executive Officer): Dr. Sergio Traversa M.B.A., Pharm.D.
IPO date: 2014-06-20
Contact
Country: US
Address: 2222 Ponce de Leon Boulevard
City: Coral Gables
State: FL
Phone: 786 629 1376
Zip Code: 33134
Other
CIK: 0001553643
ISIN: US75955J4022
CUSIP: 75955J402
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
